TheraVet S.A.

As of December 31, 2023, TheraVet S.A. has 3.22M shares outstanding.

These figures are as of December 31, 2023. The price-to-sales ratio is 4.34, and the price-to-book ratio stands at -0.85.

These figures are as of December 31, 2023. The EV/Sales ratio of 4.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. TheraVet S.A. trades at an EV/FCF ratio of 13.38, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2023, TheraVet S.A. maintains a current ratio of 3.40, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.17, indicating elevated leverage, while an interest coverage ratio of -78.85 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -18.44, reflecting losses generated across the asset base. Inventory turnover of 15.01 indicates how many times TheraVet S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on February 24, 2025, TheraVet S.A.'s stock has declined approximately 92.74% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.22.

Over the twelve months ended December 31, 2023, TheraVet S.A. posted a gross margin of -49.24, reflecting its pricing power and cost economics. The operating margin of -201.76 and net profit margin of -145.70 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2023. Free cash flow yield stands at 6.90, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -4.04, meaning TheraVet S.A. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2023, TheraVet S.A. has an Altman Z-Score of -3.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.